Editorial Comment.
作者信息
Passarelli Rachel, Lichtbroun Benjamin, Ghodoussipour Saum, Packiam Vignesh T
机构信息
Section of Urologic Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
出版信息
J Urol. 2025 Feb;213(2):215-216. doi: 10.1097/JU.0000000000004308. Epub 2024 Dec 3.
Abstract
摘要
相似文献
1
Editorial Comment.编辑评论。
J Urol. 2025 Feb;213(2):215-216. doi: 10.1097/JU.0000000000004308. Epub 2024 Dec 3.
2
Editorial Comment: Heterogeneity of Bone Marrow Stromal Cells Editorial Comment on Dr. Waller's Paper.编辑评论：骨髓基质细胞的异质性 对沃勒博士论文的编辑评论
Hematology. 1999;4(1):45-6. doi: 10.1080/10245332.1999.11746429.
3
Comment on Furst's Editorial: Postmarketing Surveys: Up Sides and Down Sides: In Reply to "Comment on Furst Editorial: Postmarketing Surveys, Upsides and Downsides".对弗斯特社论的评论：上市后调查：优点与缺点：回应《对弗斯特社论的评论：上市后调查，优点与缺点》
J Clin Rheumatol. 2003 Aug;9(4):280-1. doi: 10.1097/01.rhu.0000081273.16685.94.
4
Editorial comment.社论评论。
Mult Scler. 2013 May;19(6):825. doi: 10.1177/1352458513486409.
5
Comment on editorial comment of May '68: dentistry as we konw it today may be headed for extinction.对1968年5月社论评论的评论：我们如今所知的牙科可能正走向消亡。
Greater St Louis Dent Soc Bull. 1968 Jun;39(6):100-1.
6
Editorial Comment on Firth et al. (2019).社论评论菲尔思等人（2019 年）的文章。
Psychosom Med. 2020 Jun;82(5):532-533. doi: 10.1097/PSY.0000000000000805.
7
Editorial comment: How true outcomes-based commissioning can really 'liberate' healthcare services.编辑评论：基于真实结果的委托究竟如何才能真正“解放”医疗服务。
Future Hosp J. 2015 Jun;2(2):150. doi: 10.7861/futurehosp.2-2-150.
8
Editorial Comment to "Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous Thromboembolism After Robot-Assisted Radical Cystectomy".对“早期检测及不同化疗预防时长对机器人辅助根治性膀胱切除术后静脉血栓栓塞的影响”的编辑评论
Int J Urol. 2025 Jul;32(7):848-849. doi: 10.1111/iju.70081. Epub 2025 Apr 24.
9
Editorial comment: the future of compositional MRI for cartilage.社论评论：软骨的成分 MRI 的未来。
Eur Radiol. 2018 Jul;28(7):2872-2873. doi: 10.1007/s00330-018-5457-4. Epub 2018 Apr 30.
10
Editorial: Urinary incontinence. An editorial comment.社论：尿失禁。一篇社论评论。
Obstet Gynecol. 1976 Mar;47(3):367-8.
本文引用的文献
1
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).使用UGN-102对复发性低级别中危非肌层浸润性膀胱癌进行初次化学消融：一项单臂、开放标签的3期试验（ENVISION）
J Urol. 2025 Feb;213(2):205-216. doi: 10.1097/JU.0000000000004296. Epub 2024 Oct 24.
2
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).UGN-102 ± 经尿道膀胱肿瘤切除术与单纯经尿道膀胱肿瘤切除术治疗低级别中危非肌肉浸润性膀胱癌的随机、对照、3 期试验（ATLAS）。
J Urol. 2023 Oct;210(4):619-629. doi: 10.1097/JU.0000000000003645. Epub 2023 Aug 7.
3
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.序贯膀胱内吉西他滨和多西他赛是卡介苗治疗中危非肌肉浸润性膀胱癌的替代方案。
Eur Urol Oncol. 2023 Oct;6(5):531-534. doi: 10.1016/j.euo.2023.06.011. Epub 2023 Jul 18.
Zotero 插件